Orikine Bio is a pioneer biotech company in the field of tailored cytokines for the treatment of immune-mediated disorders.
Orikine Bio has raised $3.2M in total funding. The most recent round was Seed. The last funding was announced in February 2026.
Orikine Bio's investors include Asabys Partners, AdBio partners, CDTI Innovación's INNVIERTE program, Ministry of Science and Innovation of Spain.
Orikine Bio is headquartered in Barcelona, Spain.
Orikine Bio is a pioneer biotech company in the field of tailored cytokines for the treatment of immune-mediated disorders.
Orikine Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Orikine Bio — Funding & Investors." VCBacked, February 2, 2026, https://www.vcbacked.co/company/orikine-bio. Accessed September 30, 2026.
VCBacked. (2026). Orikine Bio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/orikine-bio
{{cite web |title=Orikine Bio — Funding & Investors |url=https://www.vcbacked.co/company/orikine-bio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated